Tag: clinical
Bio-Thera Solutions Announces Positive Phase 1 Clinical Data for BAT8006 (Folate…...
GUANGZHOU, China, Aug. 12, 2023 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative assets and biosimilars,...
Bio-Thera Solutions Announces Positive Phase 1 Clinical Data for BAT8006 (Folate…...
GUANGZHOU, China, Aug. 12, 2023 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative assets and biosimilars,...
Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for …...
LOS ANGELES, July 25, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. ("Nexcella", "Company", "We" or "Us"), today announced that updated NXC-201 relapsed/refractory...
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progr… – Press...
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer's DiseaseSmall molecule varoglutamstat, with potential for meaningful...
Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTO…...
Regulatory News:
Sensorion (FR0012596468 – ALSEN) ALSEN a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and...
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential...
The partnership focuses on combining novel antibody-drug conjugates RC88 and RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomesYANTAI, China, July 9,...
Global Clinical Biomarkers Market Report 2023: Technological Advancements and Ri… –...
DUBLIN, July 3, 2023 /PRNewswire/ -- The "Clinical Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027" report has been added...
New ENRICH-PLUS Study Builds on World’s First Positive Clinical Trial for...
NICO awards University of Maryland $200,000 for first-of-its-kind study combining MIPS with neuroprotectant for basal ganglia ICHINDIANAPOLIS, June 22, 2023 /PRNewswire/ -- Just two...
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study...
Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients...
Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomeni… –...
– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) –– 33% (2/6) of patients with...